Deutetrabenazine is a Small Molecule owned by Teva Pharmaceutical Industries, and is involved in 18 clinical trials, of which 13 were completed, and 5 are ongoing.

Deutetrabenazine (SD-809) is a reversible inhibitor of the vesicular monoamine transporter 2 (VMAT-2). Monoamines are responsible for the hyperkinetic movement disorders. It is a reversible depletor of monoamines such as dopamine, serotonin, norepinephrine, and histamine from nerve terminals. Deuterium substituted tetrabenazine binds to vesicular monamine transporters (VMATs). The transporters exchange protons for monoamines, using a proton electrochemical gradient generated by a vacuole ATP-dependent H+ pump. SD-809 inhibits the uptake of monoamines into synaptic vesicles and diminishes their output at synapses.

The revenue for Deutetrabenazine is expected to reach a total of $17.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Deutetrabenazine NPV Report.

Deutetrabenazine is currently owned by Teva Pharmaceutical Industries.

Deutetrabenazine Overview

Deutetrabenazine (SD-809, Austedo) is a synthetic deuterium substituted analogue of tetrabenazine. It is formulated as coated tablets and tablets for oral route of administration. Deutetrabenazine is indicated for the treatment of of chorea associated with Huntington’s disease, and tardive dyskinesia in adults.

Deutetrabenazine (SD-809) is under development for the treatment of dystonia and dyskinesia in cerebral palsy (athetoid cerebral palsy). It was also under development for the treatment of Tourette syndrome in pediatrics and chorea associated with Huntington's disease.

Teva Pharmaceutical Industries Overview

Teva Pharmaceutical Industries (Teva) discovers, develops, manufactures, and commercializes generic and specialty medicines. The company provides specialty medicines to treat disorders of the central nervous system (CNS), respiratory, dermatology, cancer, women’s health, and other disease conditions. It offers generic medicines in a range of dosage forms including capsules, tablets, injectables, liquids, inhalants, creams, and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It focuses on developing new generic drugs. The company conducts its worldwide operations through a network of subsidiaries in regions such as North America, Europe, and International Markets. Teva is headquartered in Tel Aviv, Israel.

The company reported revenues of (US Dollars) US$15,878 million for the fiscal year ended December 2021 (FY2021), a decrease of 4.7% over FY2020. The operating profit of the company was US$1,716 million in FY2021, compared to an operating loss of US$3,572 million in FY2020. The net profit of the company was US$417 million in FY2021, compared to a net loss of US$3,991 million in FY2020. The company reported revenues of US$3,595 million for the third quarter ended September 2022, a decrease of 5% over the previous quarter.

Quick View – Deutetrabenazine

Report Segments
  • Innovator (NME)
Drug Name
  • Deutetrabenazine
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.